Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 5/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28799952 | 1.00 | AOC3 (0.42) | AOC3MTNR1AMTNR1BLMNAHRH1 | |
| SCHEMBL143657 | 0.88 | POLB (0.45) | MTNR1AMTNR1BHRH1HTR2APOLB | |
| SCHEMBL6723122 | 0.86 | NAAA (0.41) | HRH1HTR2APOLBSIGMAR1 | |
| SCHEMBL6723008 | 0.85 | NAAA (0.43) | HTR2APOLBSIGMAR1 | |
| SCHEMBL7458136 | 0.85 | NAAA (0.43) | HTR2APOLBSIGMAR1 | |
| SCHEMBL6719347 | 0.85 | NAAA (0.43) | HTR2APOLBSIGMAR1 | |
| SCHEMBL7452348 | 0.85 | NAAA (0.43) | HTR2APOLBSIGMAR1 | |
| SCHEMBL7455004 | 0.85 | NAAA (0.43) | HTR2APOLBSIGMAR1 | |
| SCHEMBL7454063 | 0.85 | NAAA (0.43) | HTR2APOLBSIGMAR1 | |
| SCHEMBL7454537 | 0.85 | NAAA (0.43) | HTR2APOLBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 823 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116063666-B | Multifunctional polyester material and preparation method and application thereof | 四川大学 | 2024-04-19 | — | — | CN | claimed |
| CN-116063666-A | Multifunctional polyester material and preparation method and application thereof | 四川大学 | 2023-05-05 | — | — | CN | claimed |
| CN-113444005-A | Method for synthesizing novel glutaric acid compound from diaryl substituted non-activated olefin | 四川大学 | 2021-09-28 | — | — | CN | claimed |
| EP-2411004-A1 | USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS | National University of Singapore (SG) | 2012-02-01 | — | — | EP | claimed |
| US-20120015923-A1 | USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-01-19 | — | — | US | claimed |
| WO-2010110748-A1 | USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2010-09-30 | — | — | WO | claimed |
| US-7375081-B2 | Therapeutic combination of a pneumocandin derivative and an antifungal agent | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | claimed |
| US-6875740-B1 | Combination of a cyclic hexapeptide with antifungal drugs for treatment of fungal pathogens | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-05 | — | — | US | claimed |
| US-6750332-B1 | HAVE VALUABLE COSMETICALLY AND PHARMACEUTICALLY USEFUL PROPERTIES, SUCH AS PROSTAGLANDIN SYNTHESIS INHIBITION; SALICIN ESTERS | COGNIS DEUTSCHLAND GMBH & CO. KG (DE) | 2004-06-15 | — | — | US | claimed |
| US-4396613-A | DEMYCINOSYLTYLOSIN, ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | claimed |
| CN-116063666-B | Multifunctional polyester material and preparation method and application thereof | 四川大学 | 2024-04-19 | — | — | CN | disclosed |
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | disclosed |
| US-20240034845-A1 | POLYMER PARTICLES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-01 | — | — | US | disclosed |
| EP-3384549-B1 | SODIUM-ION ELECTROLYTE COMPOSITION | UNIV DEAKIN (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-4181800-A | ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-01 | — | — | US | disclosed |
| US-4088537-A | BIOTRANSFORMATION | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4041055-A | SULFENYLATION, MICHAEL ADDITION, REACTION WITH THIOPHILE, HYDROLYSIS | THE UPJOHN COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
| US-4008228-A | Process for preparing 3-methyl-3-cephem antibiotics | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-3933806-A | Cephalosporin michael adducts | ELI LILLY AND COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015923-A1 | USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS | NFKBIA, CCL11, IL5 | AOC3 2006/4885MTNR1A 856/4885MTNR1B 448/4885 |
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | AOC3 1772/4885MTNR1A 1398/4885MTNR1B 1272/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | AOC3 1772/4885MTNR1A 1398/4885MTNR1B 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.